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SUMMARY  
 
Severe obesity is a rapidly growing global health threat. Although often attributed to unhealthy lifestyle 
choices or environmental factors, obesity is known to be heritable and highly polygenic – the majority of 
inherited susceptibility is related to the cumulative impact of many common DNA variants. Here, we 
derive and validate a new polygenic predictor comprised of 2.1 million common variants to quantify this 
susceptibility and test this predictor in >300,000 individuals ranging from middle age to birth. Among 
middle-aged adults, we observe a 13 kg gradient in weight and a 25-fold gradient in risk of severe 
obesity across polygenic score deciles. In a longitudinal birth cohort, we note minimal difference in 
birthweight across score deciles, but a significant gradient emerged in early childhood and reached 12 kg 
by age 18 years. This new approach to quantify inherited susceptibility to obesity using affords new 
opportunities for clinical prevention and mechanistic assessment. 
 
 
 
  
  
INTRODUCTION 
 
Severe obesity, defined as body mass index (BMI)  40 kg/m2, is a rapidly growing public health issue 
already afflicting 8% of American adults (Flegal et al., 2016; NHLBI Expert Panel, 1998). Although present 
in less than 1% of the population in middle-income countries such as India and China, prevalence of 
severe obesity in these countries has increased more than 100-fold over the last three decades and 
shows no signs of slowing (NCD Risk Factor Collaboration, 2017). Individuals with severe obesity are 
often stigmatized due to the commonly-held belief that their condition results primarily from unhealthy 
lifestyle choices (Tomiyama et al., 2018). However, obesity is known to be heritable, suggesting that 
inborn DNA variation confers increased susceptibility in some individuals and protection in others  (Elks 
et al., 2012; Maes et al., 1997; Whitaker et al., 1997; Yang et al., 2015). 
 
Inherited susceptibility to obesity can, in rare cases, be attributed to a large-effect mutation that 
perturbs energy homeostasis or fat deposition (Barsh et al., 2000). For example, genetic inactivation of 
the melanocortin 4 receptor (MC4R) gene is associated with obesity in both mouse models and humans 
(Farooqi et al., 2003; Huszar et al., 1997; Vaisse et al., 1998; Yeo et al., 1998). However, for the vast 
majority of severely obese individuals, no such monogenic mutation can be identified (Larsen et al., 
2005; Stutzmann et al., 2008; Vaisse et al., 2000). Their genetic susceptibility may instead result from 
the cumulative impact of numerous variants with individually modest effect – a ‘polygenic’ model. This 
paradigm is similar to other complex diseases in which polygenic inheritance, involving many common 
genetic variants, accounts for the majority of inherited susceptibility (Golan et al., 2014; International 
Schizophrenia et al., 2009; Visscher et al., 2012; Yang et al., 2011; Zhu et al., 2015). 
  
A recently published genome-wide association study (GWAS) quantified the relationship between 
each of 2.1 million common genetic variants and BMI in over 300,000 individuals (Locke et al., 2015). 
None of the individual variants accounts for a large proportion of the phenotype. The strongest 
association was noted for a common variant at the FTO locus: the risk allele was associated with a 
statistically robust, but clinically modest, increase in weight of approximately 1 kilogram per inherited 
risk allele. Obtaining meaningful predictive power thus requires aggregating information from many 
common variants into a polygenic score (Chatterjee et al., 2016; Khera et al., 2018a). However, previous 
efforts to create an effective polygenic score for obesity have had only modest success (Loos and 
Janssens, 2017). 
 
Here, we use recently developed computational algorithms and large datasets to derive, validate 
and test a robust polygenic predictor of BMI and obesity. This genome-wide polygenic score (GPS) 
integrates all available common variants into a single quantitative measure of inherited susceptibility. It 
identifies a subset of the adult population that is at substantial risk of severe obesity – in some cases 
equivalent to rare monogenic mutations – and others that enjoy considerable protection. The GPS is 
associated with only minimal differences in birthweight, but it predicts clear differences in weight during 
early childhood and profound differences in weight trajectory and risk of developing severe obesity in 
subsequent years. 
 
 
  
  
RESULTS 
 
In order to create a GPS, we obtained the average effects for each of 2,100,302 genetic variants on 
BMI from the largest published GWAS study of obesity to date (Locke et al., 2015). We used a recently 
developed computational algorithm to reweight each variant according to the effect size and strength of 
statistical significance observed in the prior GWAS, the degree of correlation between a variant and 
others nearby, and a tuning parameter that denotes the proportion of variants with non-zero effect size 
(Vilhjalmsson et al., 2015). Because the best choice of this tuning parameter is difficult to know a priori, 
a range of 5 values was tested as previously recommended (Vilhjalmsson et al., 2015).  
 
We set out to validate these 5 scores—and to choose the best score for further analysis—by testing 
their ability to predict measured BMI in a validation dataset of 119,951 middle-aged adult participants of 
the UK Biobank. The UK Biobank enrolled participants aged 40 to 69 years from across the United 
Kingdom and allows for linkage of measurements such as BMI to extensive genetic data (Bycroft et al., 
2018; Sudlow et al., 2015). Within this dataset we estimated the heritability of BMI explained by 
common variants to be 23.4% using a recently developed approach (Bulik-Sullivan et al., 2015), 
consistent with prior estimates ranging from 17 to 27% (Yang et al., 2015; Yang et al., 2011; Zhu et al., 
2015). 
 
Each of the five candidate GPSs was strongly associated with observed BMI (p < 0.0001), with similar 
correlation coefficients ranging from 0.283 to 0.292 (See also Table S1). Nearly identical results were 
obtained after adjustment of each of the candidate GPSs for genetic background, as assessed by 
principal components of ancestry (Table S2). We selected the best score, with correlation of 0.292, to 
take forward into four testing datasets below. Additional details of GPS derivation and validation are 
provided in Figure 1 and the STAR Methods. 
 
Our GPS of 2,100,302 variants had substantially greater predictive power than a sixth polygenic 
score comprised of only the 141 independent variants that had reached genome-wide levels of 
statistical significance in the prior GWAS. Within the 119,951 participants in the validation dataset, 
correlation with BMI for this 141-variant score was only 0.133. This lower strength of association using 
fewer variants is consistent with earlier studies, where predictors of up to 97 variants had a relatively 
low correlation with measured BMI, ranging from 0.01 to 0.12 (Belsky et al., 2013; Hung et al., 2015; Li 
et al., 2010; Sandholt et al., 2010).  
 
Having derived and validated a new polygenic predictor which considerably outperformed earlier 
scores, we explored the predictive power of the GPS on BMI, weight, and severe obesity in 306,135 
individuals of four independent testing datasets, spanning the age spectrum from middle age to time of 
birth (Table 1). 
 
Polygenic susceptibility to weight and severe obesity in middle age 
 
We determined the extent to which the GPS predicted weight and severe obesity in a testing 
dataset of 288,016 middle-aged participants of the UK Biobank (independent of the 119,951 validation 
dataset participants studied above). Participant mean age was 57 years and 55% were female. Mean 
weight was 78.1 kilograms and mean BMI was 27.4 kg/m2. 23.9% of the participants were obese (BMI  
30 kg/m2) and 1.8% met criteria for severe obesity.  
 
  
The GPS approximated a normal distribution in the population (Figure S1). The correlation of the 
GPS and observed BMI was 0.29, identical to the UK Biobank validation dataset. Correlations were 
similar when participants were stratified into 5-year age bins, ranging from 0.28 to 0.31 (Table S3).  
 
We next stratified the population according to GPS decile and found a striking gradient with respect 
to BMI, weight, and prevalence of obesity (Figure 2A-2C). For example, average BMI was 30.0 kg/m2 for 
those in the top decile of the GPS and 25.2 kg/m2 for those in the bottom decile, a difference of 4.8 
kg/m2 (p < 0.0001). Similarly, average weight was 85.3 kilograms for those in the top decile versus 72.2 
kilograms for those in the bottom decile, a difference of 13.0 kilograms (p < 0.0001). 43.2% of those in 
the top decile were obese versus 9.5% of those in the bottom decile (Figure S2). Severe obesity was 
present in 1,621 of 28,784 (5.6%) of those in the top decile of the GPS versus 69 of 28,834 (0.2%) of 
those in the bottom decile, corresponding to a 25-fold gradient in risk of severe obesity (p < 0.0001). 
 
 Despite the strength of these associations, polygenic susceptibility to obesity is not deterministic. 
Among those in the top decile of the GPS, 83% were overweight or obese but 17% had BMI within the 
normal range and 0.2% were underweight (Figure 2D). These results were nearly identical after 
adjustment of the GPS for genetic background, as assessed by principal components of ancestry (Figure 
S3). 
 
High polygenic score common among those with extreme obesity 
 
Traditional analyses of rare genetic mutations are performed by comparing heterozygous mutation 
carriers to noncarriers. An important example is the p.Tyr35Ter premature stop codon present in 0.02% 
of the population and typically inherited as a shared haplotype with the p.Asp37Val missense mutation, 
which has been previously shown to completely inactivate MC4R activity in in vitro functional assays 
(Larsen et al., 2005; Xiang et al., 2006). A recent analysis linked this variant to an average weight 
increase of 7 kilograms (Turcot et al., 2018).  
 
We sought to mimic this approach using the GPS by labeling the top decile of the GPS distribution as 
‘carriers’ and those in the remainder of the distribution as non-carriers (Figure 3A). The 10% of the 
population who carried  ‘high GPS’ demonstrated an average BMI that was 2.9 kg/m2 higher and weight 
8.0 kilograms higher than noncarriers (p < 0.0001 for both comparisons). Results were similar when high 
GPS carriers were compared to individuals within the middle quintile of the score distribution instead of 
the bottom 90% of the distribution, with difference in BMI and weight of 2.6 kg/m2 and 7.4 kilograms, 
respectively. 
 
Furthermore, the magnitude of risk conferred by high GPS increased at more extreme levels of 
observed obesity. The proportion of high GPS carriers was 9.7% among individuals with BMI < 40 kg/m2; 
31% among the 5,232 individuals with BMI  40 kg/m2; 42.3% among the 331 individuals with BMI  50 
kg/m2; and 61.5% among the 26 individuals with BMI  60 kg/m2. Compared with the remainder of the 
GPS distribution, high GPS was associated with a 4.2, 6.6, and 14.4-fold increased risk of BMI  40, 50, 
and 60 kg/m2, respectively (Figure 3B). 
 
Another indicator of extreme obesity involves individuals who undergo treatment with bariatric 
surgery, acknowledging that factors in addition to severity of obesity contribute to the decision to move 
forward with an invasive procedure to assist with weight loss. We identified 208 such participants in the 
UK Biobank testing dataset, of whom 81 (38.9%) carried high GPS. This finding was replicated among 
714 severely obese patients treated with bariatric surgery within the Partners HealthCare System 
  
(Hatoum et al., 2013; Karlson et al., 2016). 238 of these 714 (33%) patients carried high GPS. A combined 
analysis of the 922 bariatric surgery participants noted high GPS in 319 (34.6%). Compared with 
remainder of the distribution, high GPS was associated with a 5.0-fold increased risk of severe obesity 
treated with bariatric surgery (Figure 3B). 
 
High polygenic score associated with increased risks for cardiometabolic disease and mortality 
 
Beyond severe obesity, individuals in the UK Biobank who carried high GPS were at increased risk for 
six common cardiometabolic diseases, including a 28% increased risk of coronary artery disease, a 72% 
increased risk for diabetes mellitus, 38% increased risk for hypertension, 34% increased risk for heart 
failure, 23% increased risk for ischemic stroke, and 41% increased risk for venous thromboembolism (p < 
0.05 for each; Figure 4). 
 
We next determined the relationship between high polygenic score and all-cause mortality. Death 
following enrollment occurred in 8,102 (2.8%) participants over a median follow-up of 7.1 years, 
including 940 (3.3%) of those in the top decile of the polygenic score distribution and 7,162 (2.8%) in the 
remainder of the distribution (p < 0.0001). In a survival analysis that additionally included time to death 
in the statistical model, high polygenic score was associated with a 19% increased risk of incident 
mortality (p < 0.0001). 
 
Polygenic score identifies 1.6% of the population with BMI increase similar to a monogenic mutation 
 
Rare inactivating mutations in the MC4R gene are among the most common monogenic mutations 
for obesity (Farooqi et al., 2003; Stutzmann et al., 2008; Vaisse et al., 2000), but few prior studies have 
analyzed gene sequencing data and performed clinical grade variant classification in a large population 
of unascertained adults.  
 
We performed whole exome sequencing of 6,547 UK Biobank participants, identifying 24 rare (allele 
frequency < 1%) protein-altering variants in the MC4R gene. A total of 54 of the 6,547 individuals (0.8%) 
harbored one of these variants. Average BMI of these 54 individuals was 30.8 kg/m2 versus 28.4 kg/m2 in 
the remainder of the population, a difference of 2.4 kg/m2 (95% confidence interval [CI] 1.0 to 3.7; p = 
0.001). 
 
Given that the majority of rare missense mutations have little or no functional impact on protein 
function (Boyko et al., 2008; Yampolsky et al., 2005), a clinical laboratory geneticist on our team who 
was blinded to participant phenotypes classified each of the 24 observed MC4R variants according to 
current clinical guidelines (Richards et al., 2015), integrating information from population allele 
frequency data, computational prediction and conservation scores, functional assay data, and prior 
reports of the variant segregating with obesity. 4 of these 24 variants met these clinical criteria as 
pathogenic or likely pathogenic for monogenic obesity, including the p.Tyr35Ter premature stop codon 
noted above, an inactivating frameshift mutation (p.Phe280AlafsX12), and two missense mutations – 
p.Arg165Gln and p.Glu61Lys – previously shown to segregate with obesity in family studies and impair 
receptor activity in functional assays. A summary of the evidence used to classify each of the 24 variants 
is provided in Table S4. 
 
A total of 9 of the 6,547 individuals harbored one of the 4 pathogenic MC4R variants, corresponding 
to a prevalence of 0.14% (95% confidence interval [CI] 0.06 to 0.26%). Subsequent unblinding of 
phenotype information revealed that average BMI of these 9 carriers was 32.5 kg/m2 as compared to 
  
28.4 kg/m2 in the remainder of the population, a difference of 4.1 kg/m2 (95% CI 0.8 to 7.3; p = 0.02). 
However, consistent with recent observations of incomplete penetrance in an adult population (Turcot 
et al., 2018), only one of the 9 carriers was severely obese. An additional 3 were obese, and the 
remaining 5 were overweight but not obese. 
 
We hypothesized that individuals in the extreme of the GPS distribution might have an increase in 
BMI that approaches or exceeds the 4.1 kg/m2 increase noted for carriers of pathogenic MC4R 
mutations, and tested progressively more extreme tails of the distribution. The top 1.6% of the GPS 
distribution had a mean BMI 4.1 kg/m2 higher than the remaining 98.4% – 31.4 versus 27.3 kg/m2, and 
9.1% of these individuals were severely obese.  
 
Young adults risk’ of developing severe obesity varies according to polygenic score 
 
Although only a small minority of individuals are severely obese in early adulthood, the prevalence 
increases rapidly over subsequent decades (NCD Risk Factor Collaboration, 2017). We hypothesized that 
the GPS might predict who would go on to develop severe obesity during the transition from young 
adulthood to middle age. We analyzed data from the Framingham Offspring and Coronary Artery Risk 
Development in Young Adults (CARDIA) studies, in which participants were weighed at an initial baseline 
assessment and at additional study visits over the subsequent decades (Feinleib et al., 1975; Friedman 
et al., 1988). We identified 3,722 young adult participants – none of whom were severely obese at time 
of baseline assessment – in whom GPS calculation was possible. Mean age at baseline assessment was 
28.0 years, 48% were female, and mean BMI was 24.2 kg/m2. These individuals were weighed at up to 8 
subsequent visits over a median follow-up of 27 years to determine incidence of severe obesity.  
 
Among individuals in the top decile of the GPS, 58 of 371 (15.6%) went on to develop severe obesity as 
compared with 5.6% of those in deciles 2—9 (Figure 5). By contrast, among those in the lowest decile, 
only 5 of 372 (1.3%) individuals went on to develop severe obesity. 
 
Impact of polygenic susceptibility emerges in early childhood 
 
Given the gradients in weight and severe obesity observed in adulthood, we next posed the 
question – at what age does this gradient first start to emerge? We explored this question in a birth 
cohort from the United Kingdom, the Avon Longitudinal Study of Parents and Children (ALSPAC); (Boyd 
et al., 2013; Fraser et al., 2013). The ALSPAC study recruited pregnant mothers in the United Kingdom 
between 1991 and 1992, and followed offspring with serial weight assessments from time of birth to 
age 18 years. We identified 7,861 participants with both weight and genotyping array data available for 
analysis. 
 
The GPS was associated with only small differences in birthweight: the mean was 3.47 kilograms for 
those in the top decile vs. 3.41 kilograms for those in the bottom decile, a difference of 0.06 kilograms (p 
= 0.02) (Figure 6A-F). By age 8 years, the difference increased to 3.5 kilograms (p < 0.0001), with mean 
weight 27.9 versus 24.3 kilograms. By age 18 years, the difference reached 12.3 kilograms (p < 0.0001). 
Strikingly, this weight difference between top and bottom GPS deciles at age 18 years (12.3 kilograms) 
was comparable to that seen in participants in the UK Biobank at mean age 57 years (13.0 kilograms). 
 
We observed similar results after converting participants’ weights to z-scores – the number of 
standard deviations a child’s weight differs from a population and age-specific normative value (Figure 
  
S4). The difference in z-score between the top and bottom deciles was 0.11 for birthweight (p = 0.03), 
but this gradient had increased to 0.75 by 8 years and 0.90 by 18 years (p < 0.0001).  
 
We modeled the trajectories of weight from birth to 18 years, stratifying individuals according to the 
top decile of the GPS distribution, deciles 2-9, and the bottom decile. This longitudinal analysis 
confirmed a separation in weight that starts in early childhood and continues to diverge into adulthood 
(Figure S5). 
 
  
  
DISCUSSION 
 
We describe a systematic approach to derive and validate a GPS, incorporating information from 2.1 
million common genetic variants, to predict polygenic susceptibility to obesity and tested the polygenic 
score in 306,135 participants from four cohorts. The GPS accurately predicted striking differences in 
weight, severe obesity, cardiometabolic disease and overall mortality in middle-aged adults, with the 
extreme of the GPS distribution inheriting susceptibility to obesity equivalent to rare monogenic 
mutations in MC4R. The score had minimal association with birthweight, but it was strongly associated 
with a gradient in weight that started to emerge in early childhood and even larger differences in weight 
and severe obesity in subsequent decades.  
 
The GPS far outperformed a score based only on the 141 variants most strongly associated with 
BMI, consistent with the highly polygenic nature of BMI and obesity. For example, in a direct comparison 
in 119,951 individuals , we observe a correlation with BMI of 0.29 for the GPS as compared with 0.13 
with the 141-variant score. This improved performance using a genome-wide set of common variants 
was anticipated by a prior theoretical projection study based on early GWAS results and an analysis that 
indicated minimal ‘missing heritability’ of BMI when accounting for the full range of observed genetic 
variation (Chatterjee et al., 2013; Yang et al., 2015). Here, we use a recently developed computational 
algorithm that explicitly models the correlation structure between variants in calculating variant 
weights(Vilhjalmsson et al., 2015). This algorithm has been shown to outperform prior methods for a 
range of complex traits including cardiovascular disease, type 2 diabetes, and educational attainment 
(Khera et al., 2018a; Lee et al., 2018).  
 
The ability to quantify inborn susceptibility using genome-wide polygenic scores is likely to be 
generalizable across a broad range of complex diseases, contingent upon availability of a large discovery 
GWAS, independent validation and testing datasets, and the heritability of a given disease explained by 
common variants (Torkamani et al., 2018). Predictive power will likely continue to improve in coming 
years as a function of larger discovery GWAS studies and improved computational algorithms that 
integrate functional genomics annotation, variant-variant interactions, and rare large-effect variants into 
the predictive model (Chatterjee et al., 2016; Zhang et al., 2018). 
 
We note that both a pathogenic MC4R mutation and the extreme of the GPS distribution 
predisposed individuals to a BMI 4.1 kg/m2 higher than the remainder of the population. However, 
despite an identical effect size, we estimate that extreme GPS has a prevalence an order of magnitude 
higher than pathogenic MC4R mutations – 1.6% versus 0.14% respectively.  
 
Both extreme polygenic score and pathogenic MC4R mutations demonstrate incomplete penetrance 
– not all carriers manifest severe obesity. This observation is consistent with recent large-scale gene 
sequencing studies across a broad range of complex diseases, including diabetes, cardiovascular disease, 
and breast cancer (Flannick et al., 2013; Khera et al., 2016; Manickam et al., 2018). Additional studies of 
large unascertained populations are needed to determine whether a larger effect size for pathogenic 
MC4R mutations is noted among children or young adults –  as has been suggested in prior reports 
(Farooqi et al., 2003; Stutzmann et al., 2008) – and the extent to which a favorable polygenic 
background can explain the absence of obesity noted among many mutation carriers.  
 
Genetic risk predictors have important potential implications for clinical medicine, because they 
identify individuals at risk before the condition has manifested. For example, individuals with high 
polygenic score for heart attack derive the greatest benefit from preventive medications such as 
  
cholesterol lowering therapy and those with the highest polygenic scores for breast cancer may benefit 
from earlier and more intensive mammography screening (Natarajan et al., 2017; Pharoah et al., 2008). 
 
Although the average BMI has increased substantially across populations, so too has the variability 
within any given population – suggesting that an increasingly obesogenic environment may have led to 
preferential ‘unmasking’ of inherited susceptibility among those with highest genetic risk (Smith, 2016; 
Yanovski and Yanovski, 2018). For example, prior studies suggest that the impact of unhealthy diet, 
physical activity, and sedentary behavior on BMI are most pronounced in those with a genetic 
predisposition (Qi et al., 2014; Qi et al., 2012; Tyrrell et al., 2017). The ability to identify high-risk 
individuals from the time of birth may facilitate targeted strategies for obesity prevention with 
increased impact or cost-effectiveness. Given that the weight trajectories of individuals in different GPS 
deciles start to diverge in early childhood, such interventions may have maximal impact when employed 
early in life.  
 
The GPS may also accelerate research insights into the molecular and physiological basis of severe 
obesity. Traditional research approaches have compared the physiology of severely obese individuals to 
lean controls. However, it is difficult to draw inferences from such studies, since observed differences 
might be either a cause or a consequence of severe obesity. The GPS permits identification of 
individuals, from the time of birth, who inherit high susceptibility and before clinical disease is manifest. 
Careful study of individuals at the extremes of a GPS distribution might uncover new causal risk factors 
or pathways underlying disease. For example, healthy individuals with high polygenic score for heart 
attack were enriched for higher blood pressure, increased cholesterol levels, and increased rates of type 
2 diabetes – each of these is a well-known and modifiable clinical risk factor (Khera et al., 2018b). 
Similarly, clinical and multi-omic profiling of those at the extremes of a GPS distribution for obesity may 
uncover the contributions and molecular correlates of pathways related to appetite regulation, fat 
storage, and microbiome perturbation and might enable identification of clinically relevant subtypes of 
severe obesity that most benefit from a given pharmacologic or behavioral intervention.  
 
Individuals who maintain normal weight despite an unfavorable GPS – or develop severe obesity 
despite a favorable GPS – may be of particular interest. The discordance between polygenic 
susceptibility and clinical phenotype in these individuals could result from a disproportionate influence 
of environment, the effect of a rare, large-effect mutation not captured by the polygenic score, or other 
undetermined factors. 
 
Finally, a clear understanding of the genetic predisposition to obesity may help to destigmatize 
obesity among patients, their health care providers, and the general public. 
 
We anticipate that our approach to constructing a robust GPS predictor of obesity will generalize 
across a range of common diseases, raising both important opportunities and potential challenges for 
clinical medicine. First, the cohorts studied here were of European ancestry – future studies are needed 
to extend this approach across additional ancestral background and ensure equitable implementation 
into clinical practice. Second, rare monogenic mutations for conditions such as obesity can sometimes 
be treated by precise targeting of the perturbed pathway (Kuhnen et al., 2016). Whether polygenic risk 
can be disaggregated into driving pathways within each individual in a similar fashion remains uncertain 
(Khera and Kathiresan, 2017). Lastly, additional work is needed to optimize genetic risk disclosure and to 
test whether this disclosure can improve disease prevention or treatment.
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MAIN FIGURE TITLES AND LEGENDS 
 
Figure 1. Derivation, validation, and testing of a genome-wide polygenic score for obesity 
 
A genome-wide polygenic score (GPS) for obesity was derived by starting with two independent 
datasets: first, a list of 2,100,302 common genetic variants and estimated impact of each on BMI from a 
large GWAS study (Locke et al., 2015), and second, genetic information from 503 individuals of European 
ancestry from the 1000 Genomes Study used to measure ‘linkage disequilibrium,’ the correlation 
between genetic variants (The 1000 Genomes Project Consortium, 2015). Candidate GPSs were derived 
using the LDPred computational algorithm, a Bayesian approach to calculate a posterior mean effect for 
all variants based on a prior (effect size and statistical significance in the previous GWAS) and 
subsequent shrinkage based on linkage disequilibrium (Vilhjalmsson et al., 2015). The five candidate 
LDPred scores vary with respect to the tuning parameter ρ (that is, the proportion of variants assumed 
to be causal), as previously recommended. A sixth polygenic score was derived based on only the 141 
independent variants that had achieved genome-wide levels of statistical significance in the previous 
GWAS. The optimal GPS was chosen based on maximal correlation with BMI in the UK Biobank 
validation dataset (N = 119,951 Europeans), and subsequently tested in multiple independent testing 
datasets of 306,135 individuals. See also Tables S1, S2, and S3. 
 
 
Figure 2. Relationship of genome-wide polygenic score distribution with body mass index, weight, and 
severe obesity 
 
288,016 middle-aged UK Biobank participants were binned into 10 deciles according to the polygenic 
score. Body mass index (Panel A), weight (Panel B), and prevalence of severe obesity (Panel C) each 
increased across deciles of the polygenic score (p < 0.0001 for each). Significant differences in clinical 
categories of obesity were noted (Panel D) when participants were stratified into three categories – 
bottom decile, deciles 2-9, and top decile. Underweight refers to BMI < 18.5 kg/m2, normal as 18.5 to 
24.9 kg/m2, overweight as 25.0 to 29.9 kg/m2, obesity as 30.0 to 39.9 kg/m2, and severe obesity as  40 
kg/m2 (NHLBI Expert Panel, 1998). See also Figures S1, S2, and S3. 
 
Figure 3. Association of high genome-wide polygenic score with extreme obesity and bariatric surgery 
 
We considered the top 10% of the distribution as a ‘carrier’ of high genome-wide polygenic score (GPS), 
represented by the shading in panel A, and compared risk of obesity-related outcomes to the remaining 
90% of the distribution. The x-axis represents the polygenic score, with values scaled to a mean of 0 and 
standard deviation 1 to facilitate interpretation. In Panel B, the relationship of high GPS to extreme 
obesity and treatment with bariatric surgery was quantified using logistic regression. 
CI – confidence interval 
 
 
Figure 4. Association of high genome-wide polygenic score with cardiometabolic diseases. 
 
The relationship of high genome-wide polygenic score (GPS), defined as the top decile of the score 
distribution, with the prevalence of six cardiometabolic diseases was determined in a logistic regression 
model within the UK Biobank testing dataset of 288,016 participants. 
CI – confidence interval 
  
  
Figure 5. Association of GPS with incident severe obesity among young adults 
 
Among 3,722 young adults in the Framingham Offspring and Coronary Artery Risk Development in 
Young Adults studies, individuals were stratified based on their GPS into three categories – bottom 
decile, deciles 2-9, and top decile. Incident severe obesity is plotted according to GPS category over a 
median follow-up of 27 years (p < 0.0001 for each between-group comparison).  
 
Figure 6. Association of obesity GPS decile with weight from birth to 18 years. 
 
Within the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort, 7,861 participants were 
stratified according to decile of the GPS distribution. Average weight and 95% confidence interval within 
each decile is displayed at 6 representative ages; corresponding sample size for number of participants 
with follow-up weight available at each time point is provided (Panels A-F). P-value for linear trend 
across deciles was 0.003 at birth (A) and < 0.0001 at all subsequent ages. See also Figure S4 and Figure 
S5. 
  
Table 1. Genome-wide polygenic score for obesity assessed in four independent testing datasets. 
 
 
UK Biobank Partners HealthCare 
Framingham 
Offspring / CARDIA  
Avon Longitudinal Study of 
Parents and Children 
N Participants 288,016 6,536 3,722 7,861 
Study Design Cross-sectional Case-control Longitudinal Longitudinal 
Age Range 40—69 years  18 years 18—40 years Birth 
Female sex 55% 61% 48% 49% 
Outcomes 
Weight, 
Severe obesity, 
Bariatric surgery, 
Cardiometabolic 
diseases, 
Mortality 
Bariatric surgery 
Incident severe obesity 
(27 years median  
follow-up) 
Weight at birth and 
subsequent visits 
(0—18 years) 
 
CARDIA – Coronary Artery Risk Development in Young Adults
  
STAR METHODS 
 
LEAD CONTACT FOR REAGENT AND RESOURCE SHARING 
 
Sekar Kathiresan, MD 
Center for Genomic Medicine 
Massachusetts General Hospital 
185 Cambridge Street, CPZN 5.821A 
Boston, MA 02114 
Email: skathiresan1@mgh.harvard.edu 
 
EXPERIMENTAL MODELS AND SUBJECT DETAILS 
 
Study cohorts. 
The UK Biobank is a large observational study that enrolled 502,617 individuals aged 40 to 69 years 
of age from across the United Kingdom beginning in 2006 (Sudlow et al., 2015). We identified 407,969 
individuals of European ancestry with genotyping array and BMI data available. Individuals in the UK 
Biobank underwent genotyping with one of two closely related genotyping arrays consisting of over 
800,000 genetic markers scattered across the genome (Bycroft et al., 2018). Additional genotypes were 
imputed centrally using the Haplotype Reference Consortium panel version 1.1, the UK10K panel, and 
the 1000 Genomes panel. To analyze individuals with a relatively homogenous ancestry and owing to 
small percentages of non-British individuals, the present analysis was restricted to the white British 
ancestry individuals. This subpopulation was constructed centrally using a combination of self-reported 
ancestry and genetic confirmation by principal components of ancestry. Additional exclusion criteria 
included outliers for heterozygosity or genotype missing rates, discordant reported versus genotypic 
sex, putative sex chromosome aneuploidy, or withdrawal of informed consent, derived centrally as 
previously reported (Bycroft et al., 2018). 
 
The genome-wide polygenic score was validated within 119,951 participants of the UK Biobank 
Phase 1 validation dataset, and subsequently tested in the remaining 288,016 participants. Avoidance of 
sample overlap between the validation and testing datasets prevents test statistic inflation (Vilhjalmsson 
et al., 2015). 
 
Whole exome sequencing was performed at the Broad Institute of MIT and Harvard (Cambridge, 
MA, USA) in a subset of 6,552 UK Biobank participants. Libraries were constructed as previously 
reported (Fisher et al., 2011) and sequenced on an Illumina HiSeq sequencer with the use of 151 bp 
paired-end reads. In-solution hybrid selection was performed using the Illumina Nextera Exome Kit. 
Aligned non-duplicate reads were locally realigned and base qualities were recalibrated using Genome 
Analysis Toolkit software (McKenna et al., 2010; Van der Auwera et al., 2013). Variants were jointly 
called using Genome Analysis Toolkit HaplotypeCaller software. We removed samples with 
contamination > 10% (N = 0), samples with < 80% of target bases at 20X coverage (N = 3), samples with 
discordance between self-reported and genetic sex (N = 0), and samples with discordant reported versus 
genotypic sex (N = 2). Mean target coverage among the remaining 6,547 samples was 75X, and 91.4% of 
target bases were captured at >20X sequencing depth.  The subset of rare (allele frequency < 1%) 
variants in the melanocortin 4 receptor gene (MC4R; Ensemble transcript ID: ENST00000299766) were 
narrowed to those meeting American College of Medical Genetics and Genomics (ACMG)/Association of 
Molecular Pathology (AMP) pathogenic or likely pathogenic criteria by an American Board of Genetics 
  
and Genomics (AMBGG)-certified clinical laboratory geneticist within the Partners HealthCare 
Laboratory for Molecular Medicine (Boston, MA, USA) who was blinded to any phenotype information 
(Richards et al., 2015). Among the 24 rare coding variants analyzed, mean sequencing depth across the 
6,547 variants was 80X with a genotype missingness rate of 0%. See also Table S4. 
 
The Partners HealthCare system case-control cohort was assembled using 718 individuals with 
severely obese individuals of European ancestry who underwent Roux-en-Y gastric bypass surgery in the 
Partners HealthCare System (Hatoum et al., 2013). 5,822 controls were derived from a population of 
European participants of the Partners HealthCare Biobank (Karlson et al., 2016). Control participants 
were excluded if they had undergone bariatric surgery or had a Charlson comorbidity index >3 (Charlson 
et al., 1987). Samples were imputed to the Haplotype Reference Consortium panel version 1.1 using the 
Michigan Imputation Server (Das et al., 2016; McCarthy et al., 2016).  
 
The Framingham Offspring Study is a prospective cohort study that recruited 5,124 individuals 
beginning in 1971 (Feinleib et al., 1975). We identified 2,177 young adults aged 18 to 40 years with 
available data on BMI. BMI was assessed at baseline and during six subsequent visits to ascertain 
incident severe obesity. Individuals with severe obesity at baseline or missing data from subsequent 
visits were excluded. 
 
The Coronary Artery Risk Development in Young Adults (CARDIA) Study is a prospective cohort study 
of 5,115 black and white participants beginning in 1985 (Friedman et al., 1988). We analyzed 1,545 
white participants aged 18 to 30 years at time of enrollment. BMI was assessed at baseline and up to 8 
subsequent visits to ascertain incident severe obesity. Individuals with missing baseline BMI, severe 
obesity at baseline, and pregnant females were excluded. 
 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective birth cohort study 
investigating factors that influence normal childhood development and growth (Boyd et al., 2013; Fraser 
et al., 2013). Briefly, 14,541 pregnant women resident in a defined area of the South West of England, 
with an expected delivery date of April 1, 1991 and December 31, 1992 were enrolled to the cohort. Of 
these, 13,988 live-born children who were still alive 1 year later have been followed-up to date with 
regular questionnaires and clinical measures, providing behavioral, lifestyle and biological data. For the 
present analysis, up to 7,861 participants with both weight and genotyping array data available were 
included. Weight was assessed at subsequent visits up to age 18 years. Z-scores were computed using 
the Growth Analyzer RCT program (https://growthanalyser.org/software/growth-analyser-rct/), with 
age-specific reference weights derived from the United Kingdom/Northern Ireland reference population. 
The study website (http://www.bristol.ac.uk/alspac/researchers/our-data/) contains details of all the 
data that are available through a fully searchable data dictionary and variable search tool.  
 
Informed consent and study approval. Ethical approval for the study was obtained from the ALSPAC 
Ethics and Law Committee and the Local Research Ethics Committee and written informed consent was 
obtained from both the parent/guardian and, after the age of 16, children provided written assent. For 
the three remaining cohorts, informed consents were obtained by investigators of each study and 
analysis approved by the Institutional Review Board of Partners HealthCare (Boston, MA). 
 
METHOD DETAILS 
 
Polygenic score derivation and validation. 
  
 
Polygenic scores provide a quantitative metric of an individuals inherited risk based on the 
cumulative impact of many common (minor allele frequency 1%) variants. Weights are generally 
assigned to each genetic variant according to the strength of its association with a given trait (effect 
estimate). Individuals are scored based on how many risk alleles they have for each variant (e.g. 0, 1, 2 
copies) included in the polygenic score. 
 
For our score derivation, we used summary statistics from a recent genome-wide association study 
(GWAS) for body mass index (BMI) including up to 339,224 individuals and a linkage disequilibrium 
reference panel of 503 European samples from 1000 Genomes phase 3 version 5 (Locke et al., 2015; The 
1000 Genomes Project Consortium, 2015). DNA polymorphisms with ambiguous strand (A/T or C/G) 
were removed from the score derivation.  
 
5 candidate polygenic scores were derived using the LDPred computational algorithm (Vilhjalmsson 
et al., 2015). This Bayesian approach calculates a posterior mean effect size for each variant based on a 
prior and subsequent shrinkage based on the extent to which this variant is correlated with similarly 
associated variants in the reference population. The underlying Gaussian distribution additionally 
considers the fraction of causal (i.e., non-zero effect sizes) markers via a tuning parameter, ρ. Because ρ 
is unknown for any given disease, a range of ρ values, the fraction of causal variants, was used – 1, 0.3, 
0.1, 0.03, 0.01. A sixth score was derived with variants restricted to those meeting genome-wide levels 
of statistical significance (p< 5 x 10-8) using the linkage disequilibrium-based clumping procedure in 
PLINK version 2.0 (Chang et al., 2015). The algorithm identifies a list of independent (r2 < 0.2) variants 
with this level of statistical significance. 
 
The 6 candidate polygenic scores were calculated in a validation dataset of 119,951 participants of 
European ancestry of the UK Biobank Phase I validation dataset. More than 99% of variants in the 
genome-wide polygenic scores were available for scoring purposes in the validation dataset with 
sufficient imputation quality (INFO > 0.3); Table S1. The polygenic score with the strongest correlation 
with observed BMI in the validation dataset was determined based on Pearson correlation, and the best 
score carried forward into subsequent analyses in independent testing datasets. A sensitivity analysis 
that included adjustment for genetic background was performed as described previously (Khera et al., 
2018b). In brief, we fit a linear regression model using the first ten principal components of ancestry to 
predict polygenic score. The residual from this model was used to create an ancestry-corrected 
polygenic score. 
 
UK Biobank Phenotypes 
 
Within the UK Biobank, severe obesity was defined as BMI  40 kg/m2 (NHLBI Expert Panel, 1998). 
Additional phenotypes with respect to disease status and bariatric surgery were ascertained via linkage 
to data based on self-report in an interview with a trained nurse, and diagnosis and procedure codes 
within the electronic health record. Bariatric surgery status was ascertained based on having a OPCS-4 
primary procedure code for Roux-en-Y gastric bypass, sleeve gastrectomy, or duodenal switch procedure 
(G28.1-5, G31.2, G 32.1, G33.1, G71.6).  
 
With respect to additional classification of prevalent cardiometabolic diseases in UK Biobank 
participants, coronary artery disease ascertainment was based on a composite of myocardial infarction 
or coronary revascularization. Myocardial infarction was based on self-report or hospital admission 
diagnosis, as performed centrally by the UK Biobank. This included individuals with International 
  
Classification of Diseases (ICD)-9 codes of 410.X, 411.0, 412.X, 429.79 or ICD-10 codes of I21.X, I22.X, 
I23.X, I24.1, I25.2 in hospitalization records. Coronary revascularization was assessed based on an OPCS-
4 coded procedure for coronary artery bypass grafting (K40.1–40.4, K41.1–41.4, K45.1–45.5) or coronary 
angioplasty with or without stenting (K49.1–49.2, K49.8–49.9, K50.2, K75.1–75.4, K75.8–75.9). Diabetes 
mellitus ascertainment was based on a composite of self-report, use of insulin, ICD-9 codes of 250.X or 
ICD-10 codes of E10.X, E11.X, E12.X, E 13.X, E14.X in hospitalization records. Hypertension 
ascertainment was based on self-report, ICD-9 codes of 40.X or ICD-10 codes of I10, I11.X, I 12.X, I13.X, 
or I15.X in hospitalization records. Heart failure was ascertained based on self-report, ICD-9 codes of 
425.4, 428.0, 428.1, 428.9 or ICD-10 codes of I11.0, I13.0, I13.2, I25.5, I42.X in hospitalization records. 
Ischemic stroke was ascertained centrally based on self-report or hospitalization admission diagnosis of 
ICD-9 codes 430, 431, 434, or 436 and ICD-10 codes of I60, I61, I63, I64. Venous thromboembolism was 
diagnosed based on self-report, ICD-9 codes of 415.1, 451.1, ICD-10 codes of I26.X, I80.X, I82.X in the 
hospitalization records or insertion of an IVC filter or open thrombectomy of lower-extremity veins in 
procedure registries. 
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
We estimated the heritability of BMI based on common variation within the validation set of the UK 
Biobank composed of 119,951 European individuals. We used previously recommended parameters 
suggested for heritability assessment using LD-score regression (Bulik-Sullivan et al., 2015). In brief, we 
tested for an association between 1,163,095 common variants that were well-imputed and available in 
HapMap3 (minor allele frequency > 0.01, imputation INFO > 0.9) and BMI using a linear regression 
model adjusted for age, sex, genotyping array, and the first 10 principal components of ancestry. We 
then estimated heritability using the resulting association statistics and a linkage disequilibrium 
reference panel of individuals of European ancestry from the 1000 Genomes Study (The 1000 Genomes 
Project Consortium, 2015). 
 
Within each of the four testing cohorts, genotyping array data was imputed and a genome-wide 
polygenic score calculated for each individual. Scores were generated by multiplying the genotype 
dosage of each risk allele for each variant by its respective weight, and then summing across all variants 
in the score. Incorporating genotype dosages accounts for uncertainty in genotype imputation. Scoring 
was done using the PLINK2 software program (Chang et al., 2015). Within the UK Biobank, participants 
were stratified according to decile of the GPS. Average weight and prevalence of severe obesity was 
determined within each decile. The relationship of high polygenic score, defined as the top decile of the 
GPS, with severe obesity and treatment with bariatric surgery was next determined in both the UK 
Biobank and Partners HealthCare system cohorts using logistic regression. 
 
Associations of high polygenic score with severe obesity, bariatric surgery, and six cardiometabolic 
diseases, were determined using logistic regression models. Association with incident all-cause mortality 
was determined using a Cox regression model survival analysis. 
 
The incidence of severe obesity among young adults according to GPS category was assessed in the 
Framingham Offspring and CARDIA studies using an unadjusted Kaplan-Meier survival analysis. 
 
Within the ALSPAC cohort, individuals were stratified according to GPS decile and mean weights 
determined within each of 6 representative ages. P-values for linear trend were assessed using GPS 
decile as a predictor of observed weight at each age. Linear spline multi-level models were used to 
  
examine the association between the polygenic score and change in weight from birth to 18 years. 
Multi-level models estimate the mean trajectories of weight while accounting for non-independence of 
repeated measures within individuals, change in scale and variance of measures over time, differences 
in the number and timing of measurements between individuals (using all available data from all eligible 
participants under a missing-at-random assumption) (Howe et al., 2016; Tilling et al., 2014). Linear 
splines allow know points to be fitted at different ages to derive periods of change that are 
approximately linear. All participants with at least one measure of weight were included under a 
missing-at-random assumption to minimize selection bias in trajectories estimated using linear spline 
multi-level models (with two levels: measurement occasion and individual). Knot points were placed at 
ages 1, 8 and 15 years based on the distribution and longitudinal pattern of weight measures between 
birth and 18 years. All trajectories were models in MLwiN version 3.01 (UoBc, 2017) called from Stata 
version 15 using the “runmlwin” command (UoBc, 2016). 
 
Statistical analyses were conducted using R version 3.4.3 software (The R Foundation) and Stata 
version 15. 
 
DATA AND SOFTWARE AVAILABILITY 
 
The genome-wide polygenic score validated and tested here will be made available to the research 
community prior to publication at: http://www.broadcvdi.org/informational/data.  
  
  
SUPPLEMENTAL FIGURE TITLES AND LEGENDS 
 
Figure S1. Distribution of the genome-wide polygenic score for obesity, Related to Figure 2. 
 
The distribution of the genome-wide polygenic score (GPS) in 288,016 participants of the UK Biobank 
testing dataset is displayed. The x-axis represents the polygenic score, with values scaled to a mean of 0 
and standard deviation 1 to facilitate interpretation.  
 
Figure S2. Relationship of genome-wide polygenic score distribution with obesity, Related to Figure 2 
 
288,016 middle-aged UK Biobank participants were binned into 10 deciles according to the polygenic 
score, with significant differences in the prevalence of obesity (body mass index  30 kg/m2) noted 
across deciles of the polygenic score (p < 0.0001).   
 
Figure S3. Relationship of genome-wide polygenic score distribution with body mass index, weight, 
and severe obesity, including adjustment for principal components of ancestry, Related to Figure 2 
 
A sensitivity analysis was performed after adjustment of the genome-wide polygenic score for genetic 
background, as assessed by the first ten principal components of ancestry. 288,016 middle-aged UK 
Biobank participants were binned into 10 deciles according to this ancestry-adjusted genome-wide 
polygenic score. Body mass index (Panel A), weight (Panel B), and prevalence of severe obesity (Panel C) 
each increased across deciles of the polygenic score (p < 0.0001 for each). Significant differences in 
clinical categories of obesity were noted (Panel D) when participants were stratified into three 
categories – bottom decile, deciles 2-9, and top decile. Underweight refers to BMI < 18.5 kg/m2, normal 
as 18.5 to 24.9 kg/m2, overweight as 25.0 to 29.9 kg/m2, obesity as 30.0 to 39.9 kg/m2, and severe 
obesity as  40 kg/m2. 
 
Figure S4. Association of obesity GPS decile with weight z-scores from birth to 18 years, Related to 
Figure 6 
 
Within the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort, 7,861 participants were 
stratified according to decile of the GPS distribution. Average z-score and 95% confidence interval within 
each decile is displayed at 6 representative ages; corresponding sample size for number of participants 
with follow-up weight available at each time point is provided (Panels A-F). P-value for linear trend 
across deciles was 0.003 at birth (A) and < 0.0001 at all subsequent ages. 
 
Figure S5. Association of GPS with longitudinal weight trajectory from birth to 18 years, Related to 
Figure 6 
  
Among 7,861 participants of the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort, 
individual were stratified based on their GPS into three categories – bottom decile, deciles 2-9, and top 
decile. Longitudinal weight trajectories from birth to 18 years were modeled using linear spline multi-
level models with knot points. 
  
  
SUPPLEMENTAL TABLE TITLES AND LEGENDS 
 
Table S4. Variant Classification of Melanocortin 4 Receptor (MC4R) gene identified by whole exome 
sequencing, Related to STAR Methods. 
 
Melanocortin 4 Receptor (MC4R) gene variants identified by exome sequencing of 6,547 UK Biobank 
participants were classified according to current clinical guidelines (Richards et al., 2015) to identify 
those that with allele frequency  < 0.01 that were pathogenic or likely pathogenic for obesity. Variants 
are described based on ‘chromosome:position:reference allele>alternate allele’ formatting, with 
chromosome positions based on the GRCh37 genome assembly.  
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